Trials / Conditions / Neurogenic Detrusor Overactivity

Neurogenic Detrusor Overactivity

22 registered clinical trials studyying Neurogenic Detrusor Overactivity — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor O NCT06596291	EG 427	Phase 1 / Phase 2
Recruiting	Improving Pelvic Rehabilitation Using Epidural Stimulation After Spinal Cord Injury NCT06515223	University College, London	N/A
Active Not Recruiting	A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children NCT05621616	Astellas Pharma Global Development, Inc.	Phase 3
Completed	Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfu NCT06059066	The Methodist Hospital Research Institute	N/A
Active Not Recruiting	Dorsal Genital Nerve Stimulation for Bladder Management After SCI NCT05502614	University College, London	N/A
Recruiting	A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC NCT05491525	Urovant Sciences GmbH	Phase 2 / Phase 3
Completed	Study To Assess The Bioequivalence Under Fed And Fasted Conditions Of The Fesoterodine Beads-In-Capsule SR4 An NCT04452838	Pfizer	Phase 1
Completed	BIOEQUIVALENCE STUDY IN HEALTHY PARTICIPANTS COMPARING 4 MG AND 8 MG FESOTERODINE EXTENDED-RELEASE TABLETS (TO NCT04478357	Pfizer	Phase 1
Completed	Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury NCT03482037	RECORDATI GROUP	Phase 1 / Phase 2
Completed	Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spina NCT03168828	Taris Biomedical LLC	Phase 1
Completed	Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detru NCT02751931	Astellas Pharma Europe B.V.	Phase 3
Completed	A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric S NCT02526979	Astellas Pharma Europe B.V.	Phase 1
Completed	A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorpti NCT02211846	Astellas Pharma Inc	Phase 1
Completed	Is the Nerve Growth Factor (NGF) a Useful Biomarker in Neurogenic Bladder Dysfunction After Spinal Cord Injury NCT02138149	Swiss Paraplegic Research, Nottwil	—
Completed	A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effec NCT01981954	Astellas Pharma Europe B.V.	Phase 3
Completed	A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participan NCT01565694	Astellas Pharma Europe B.V.	Phase 3
Completed	Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder NCT01539707	Astellas Pharma Inc	Phase 1
Withdrawn	Treatment of Neurogenic Detrusor Overactivity: Early Versus Late Pudendal Nerve Stimulation in Spinal Cord Inj NCT01043848	Ulrich Mehnert	N/A
Completed	Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years NCT00857896	Pfizer	Phase 2
Terminated	A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral NCT00712322	Warner Chilcott	Phase 2
Completed	Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurog NCT00800462	Toronto Rehabilitation Institute	Phase 4
Completed	Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity NCT01091727	Sunnybrook Health Sciences Centre	Phase 3